Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.73 |
| ▸ | MET | P08581 | 1/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.51 |
| ▸ | NPM1 | P06748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21846976 | 0.84 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL21846967 | 0.82 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL21846975 | 0.81 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL21846990 | 0.79 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL21847020 | 0.79 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL21847025 | 0.77 | EGFR (1.00) | EGFRMETALK | |
| SCHEMBL22028768 | 0.73 | EGFR (0.56) | EGFRMETALKNPM1 | |
| SCHEMBL22028767 | 0.73 | EGFR (0.56) | EGFRMETALKNPM1 | |
| SCHEMBL1545887 | 0.72 | ALK (0.51) | EGFRMETALKNPM1 | |
| SCHEMBL21847011 | 0.71 | EGFR (1.00) | EGFRMETALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | FLT3, EGFR, ERBB2 | EGFR 2/4885MET 169/4885ALK 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.